Stock QNCX QUINCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
1.06 USD +6.00% Intraday chart for Quince Therapeutics, Inc. +6.00% +0.95%
Apr. 01 Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 26 Transcript : Quince Therapeutics, Inc. - Special Call

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
BU
Transcript : Quince Therapeutics, Inc. - Special Call
North American Morning Briefing : Markets Steady -2-
DJ
Quince Therapeutics Launches Scientific Advisory Board
BU
Quince Therapeutics, Inc. Launches Scientific Advisory Board
CI
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
BU
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors
CI
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
BU
Quince Therapeutics to Participate at Investor Events in January 2024
BU
North American Morning Briefing : All Eyes on -2-
DJ
Quince Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Quince Therapeutics : Investor Presentation – November 2023
PU
Quince Therapeutics, Inc. Appoints Brendan Hannah to the Position of Chief Operating Officer
CI
Quince Therapeutics, Inc. Appoints Luca Benatti as Director
CI
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
BU
Quince Therapeutics, Inc. acquired EryDel S.p.A
CI
Quince Says US FDA Lifts Partial Clinical Hold on EryDel's Treatment for Ataxia-Telangiectasia
MT
Quince Therapeutics to Advance Study of EryDex as FDA Lifts Application Hold
DJ
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QNCX Stock
  4. News Quince Therapeutics, Inc.